Preliminary results of a multicenter, randomized study on the effect of natural interferon beta (n-INFN-β) in relapsing-remitting MS are reported. Sixty patients received either no treatment or n-IFN-β) (9 MIU three times a week, subcutaneously). After 6 months, the n-IFN-β-treated group showed a 58% median reduction in the number of active lesions detected on monthly magnetic resonance imaging scans as well as a 38% reduction in the exacerbation rate as compared with the control group. Side-effects were mild and self-limiting. The study continues according to the protocol.
JacobsL
. (1986) Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet2: 1411-1413.
7.
JohnsonRL
. (1990). Recombinant human beta interferon treatment of relapsing-remitting multiple sclerosis: Pilot study results. Neurology40 (suppl. 1): 261(Abstract 538P)
8.
IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43: 655-661.
9.
PatyDW
. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43: 662-667.
10.
NautaJJP
. (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel groups and crossover designs. J Neurol Sci122: 6-14.
11.
PatyDW. (1988) Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci15: 266-272.
12.
McDonaldWI. (1993) The dynamics of multiple sclerosis. J Neurol240: 28-36.
13.
McDonaldWI, MillerDH, ThompsonAJ. (1994) Are magnetic resonance findings predictive of clinical out-come in therapeutic trials in multiple sclerosis? The dilemma of interferon-β. American Neurological" Association14-18.
14.
PoserCM
. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol13(3): 227-231.
15.
JacobsL
. (1994) The results of a phase III trial of recombinant beta interferon (BIOGEN’S IFN-β-1A) as treatment for multiple sclerosis. Fourth International Congress of Neuroimmunology, Amsterdam, October1994.
